4SC Announces Financial Results for the First Quarter of 2015
4SC AG (Frankfurt, Prime Standard: ISIN DE000A14KL72, VSC), a discovery and development company of targeted small molecu…
4SC AG (Frankfurt, Prime Standard: ISIN DE000A14KL72, VSC), a discovery and development company of targeted small molecu…
4SC AG (Frankfurt, Prime Standard: ISIN DE000A14KL72, VSC), a discovery and development company of targeted small molecu…
Medigene AG (MDG1, Frankfurt, Prime Standard) announces that early clinical data of its dendritic cell (DC) vaccines wer…
Medigene AG (MDG1, Frankfurt, Prime Standard) published preliminary financial results for the fiscal year 2014. The comp…
4SC AG (Frankfurt, Prime Standard: VSC) today decided to hold an Extraordinary General Meeting on 11 March 2015. The pri…
Medigene AG (MDG1, Frankfurt, Prime Standard) announces that two presentations on its antigen-tailored dendritic cell (D…
Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation in five international conferences: BIO-Euro…
Medigene AG (MDG1, Frankfurt, Prime Standard) announced today that a scientific article on its dendritic cell (DC) vacci…
The biotech company Medigene AG (Frankfurt: MDG1, Prime Standard) announces that the Australian Patent Office has issued…
. - Phase I confirms safety and tolerability of resminostat/docetaxel combination in the planned dose regimen in Asian…